Tyra Biosciences (NASDAQ:TYRA) Research Coverage Started at UBS Group

UBS Group initiated coverage on shares of Tyra Biosciences (NASDAQ:TYRA) in a report issued on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $28.00 price objective on the stock.

A number of other equities analysts have also commented on the stock. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. HC Wainwright reduced their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Finally, Oppenheimer boosted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA opened at $15.97 on Tuesday. The company has a market capitalization of $808.13 million, a P/E ratio of -9.92 and a beta of 1.04. Tyra Biosciences has a 1 year low of $11.32 and a 1 year high of $29.60. The business’s 50 day simple moving average is $15.48 and its 200 day simple moving average is $19.22.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, sell-side analysts anticipate that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the sale, the director now owns 472,207 shares of the company’s stock, valued at $7,635,587.19. The trade was a 2.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Alan Fuhrman purchased 9,500 shares of Tyra Biosciences stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at approximately $205,584. The trade was a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 84,160 shares of company stock valued at $1,827,047. Company insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. HighVista Strategies LLC purchased a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $257,000. Franklin Resources Inc. bought a new position in shares of Tyra Biosciences in the third quarter worth approximately $278,000. Valence8 US LP purchased a new stake in Tyra Biosciences during the 3rd quarter valued at $310,000. SG Americas Securities LLC bought a new stake in Tyra Biosciences in the 3rd quarter worth about $311,000. Finally, The Manufacturers Life Insurance Company bought a new position in Tyra Biosciences during the third quarter valued at approximately $333,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.